StocksFundsScreenerSectorsWatchlists
AXGN

AXGN - AxoGen Inc Stock Price, Fair Value and News

7.94USD+0.17 (+2.19%)Delayed as of 28 Mar 2024, 10:57 am ET

Market Summary

AXGN
USD7.94+0.17
Delayedas of 28 Mar 2024, 10:57 am
2.19%

AXGN Alerts

  • 3 major insider sales recently.
  • Losses in recent quarter

AXGN Stock Price

View Fullscreen

AXGN RSI Chart

AXGN Valuation

Market Cap

335.7M

Price/Earnings (Trailing)

-15.46

Price/Sales (Trailing)

2.11

EV/EBITDA

-52.95

Price/Free Cashflow

-17.14

AXGN Price/Sales (Trailing)

AXGN Profitability

EBT Margin

-9.15%

Return on Equity

-22.7%

Return on Assets

-11.03%

Free Cashflow Yield

-5.83%

AXGN Fundamentals

AXGN Revenue

Revenue (TTM)

159.0M

Rev. Growth (Yr)

18.69%

Rev. Growth (Qtr)

4%

AXGN Earnings

Earnings (TTM)

-21.7M

Earnings Growth (Yr)

28.11%

Earnings Growth (Qtr)

4.79%

Breaking Down AXGN Revenue

52 Week Range

7.95
(Low)(High)

Last 7 days

-4.3%

Last 30 days

-30.7%

Last 90 days

5%

Trailing 12 Months

-10.6%

How does AXGN drawdown profile look like?

AXGN Financial Health

Current Ratio

2.89

Debt/Equity

0.48

Debt/Cashflow

-0.12

AXGN Investor Care

Shares Dilution (1Y)

1.42%

Diluted EPS (TTM)

-0.52

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023144.2M147.9M152.3M159.0M
2022127.3M128.2M134.0M138.6M
2021119.1M130.5M128.3M127.4M
2020107.7M103.1M108.0M112.3M
201990.0M96.1M102.0M106.7M
201865.4M70.9M77.5M83.9M
201745.2M50.0M54.9M60.4M
201630.5M34.5M37.5M41.1M
201518.6M20.8M24.3M27.3M
201411.9M13.3M15.0M16.8M
20138.2M9.0M10.0M10.9M
20125.4M6.2M7.0M7.7M
20113.5M3.9M4.4M4.8M
20100003.0M

Tracking the Latest Insider Buys and Sells of AxoGen Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 21, 2024
scopelianos angelo
acquired
-
-
2,500
chief r&d officer
Mar 21, 2024
donovan michael patrick
sold
-46,333
7.68
-6,033
vp operations
Mar 21, 2024
devinney erick wayne
sold
-35,159
7.68
-4,578
chief innovation officer
Mar 21, 2024
zaderej karen l.
sold
-301,670
7.68
-39,280
ceo
Mar 21, 2024
scopelianos angelo
sold
-52,846
7.68
-6,881
chief r&d officer
Mar 16, 2024
devinney erick wayne
acquired
-
-
18,675
chief innovation officer
Mar 16, 2024
donovan michael patrick
acquired
-
-
24,575
vp operations
Mar 16, 2024
zaderej karen l.
acquired
-
-
110,322
ceo
Mar 16, 2024
scopelianos angelo
acquired
-
-
25,406
chief r&d officer
Mar 07, 2024
donovan michael patrick
sold
-319,891
8.81
-36,310
vp operations

1–10 of 50

Which funds bought or sold AXGN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 11, 2024
VANGUARD GROUP INC
reduced
-0.53
4,446,730
16,839,300
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
1,281
6,587,200
6,955,860
-%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
reduced
-0.4
36,578
138,048
-%
Feb 26, 2024
PERCEPTIVE ADVISORS LLC
reduced
-7.71
1,141,740
5,521,240
0.12%
Feb 20, 2024
Quarry LP
reduced
-71.78
-10,813
6,782
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
reduced
-12.22
31,000
188,000
-%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
new
-
427,000
427,000
0.04%
Feb 15, 2024
Farther Finance Advisors, LLC
new
-
615
615
-%
Feb 15, 2024
JANE STREET GROUP, LLC
new
-
516,580
516,580
-%
Feb 15, 2024
Empire Financial Management Company, LLC
added
17.25
180,490
480,490
0.19%

1–10 of 48

Are Funds Buying or Selling AXGN?

Are funds buying AXGN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AXGN
No. of Funds

Unveiling AxoGen Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
arrowmark colorado holdings llc
11.97%
5,152,300
SC 13G/A
Feb 13, 2024
vanguard group inc
5.73%
2,465,496
SC 13G
Feb 12, 2024
morgan stanley
6.6%
2,859,421
SC 13G
Feb 02, 2024
soleus capital master fund, l.p.
6.0%
2,595,815
SC 13G/A
Jan 26, 2024
blackrock inc.
7.8%
3,342,773
SC 13G/A
Aug 11, 2023
soleus capital master fund, l.p.
8.2%
3,541,298
SC 13G
Aug 10, 2023
arrowmark colorado holdings llc
10.34%
4,431,629
SC 13G/A
Feb 14, 2023
point72 asset management, l.p.
4.3%
1,815,000
SC 13G/A
Feb 03, 2023
first light asset management, llc
4.59%
1,942,270
SC 13G
Jan 31, 2023
blackrock inc.
7.5%
3,159,410
SC 13G/A

Recent SEC filings of AxoGen Inc

View All Filings
Date Filed Form Type Document
Mar 25, 2024
4
Insider Trading
Mar 25, 2024
4
Insider Trading
Mar 25, 2024
4
Insider Trading
Mar 25, 2024
4
Insider Trading
Mar 13, 2024
EFFECT
EFFECT
Mar 08, 2024
4
Insider Trading
Mar 08, 2024
4
Insider Trading
Mar 08, 2024
8-K
Current Report
Mar 07, 2024
144
Notice of Insider Sale Intent
Mar 07, 2024
144
Notice of Insider Sale Intent

What is the Fair Value of AXGN?

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Cheap
or
Expensive?


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks

Peers (Alternatives to AxoGen Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
196.9B
40.1B
-3.02% 19.11%
34.4
4.91
-8.12% -17.45%
71.2B
19.5B
2.28% 4.53%
56.69
3.65
4.02% -22.04%
24.6B
3.9B
3.45% 0.50%
55.33
6.38
3.42% 23.09%
21.7B
14.8B
1.75% 11.60%
8.16
1.46
2.12% 209.17%
MID-CAP
10.2B
2.7B
2.92% -30.26%
-16.04
3.83
-4.68% 82.43%
9.7B
12.3B
-3.34% -3.19%
23.21
0.78
-2.44% -22.68%
9.5B
3.5B
2.97% 25.27%
33.57
2.74
4.97% 18.89%
6.9B
4.0B
-2.47% -11.08%
-51.36
1.74
1.10% 85.84%
3.5B
366.4M
0.74% 28.92%
-577.22
9.59
33.86% 89.80%
2.5B
6.6B
-3.84% 3.03%
12.86
0.38
2.78% -0.87%
SMALL-CAP
1.5B
3.2B
47.53% -25.51%
-2.23
0.47
7.73% -1066.14%
379.3M
166.7M
5.16% -2.53%
-4.59
2.28
6.67% -456.34%
227.2M
329.5M
-13.41% -54.45%
-16.09
0.69
0.49% 64.22%
43.3M
52.3M
-46.12% -38.06%
-2.31
0.83
17.61% 19.28%
4.5M
3.7M
2.40% 338.46%
-0.37
1.19
5.77% 8.23%

AxoGen Inc News

Latest updates
Simply Wall St • 3 hours ago
Defense World • 26 Mar 2024 • 08:37 am
Simply Wall St • 10 Mar 2024 • 08:00 am
Yahoo Finance • 08 Mar 2024 • 08:00 am
Yahoo Finance • 06 Mar 2024 • 08:00 am
InvestorsObserver • 05 Mar 2024 • 08:00 am
CNN • 4 months ago

AxoGen Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue4.0%42,922,00041,271,00038,155,00036,664,00036,164,00036,959,00034,454,00031,007,00031,537,00031,204,00033,580,00031,037,00032,495,00033,428,00022,116,00024,261,00028,162,00028,564,00026,701,00023,285,00023,433,000
Gross Profit1.6%33,764,00033,228,00030,927,00029,955,00030,023,00030,783,00028,170,00025,461,00026,109,00025,965,00026,488,00025,865,00027,032,00027,731,00016,511,00019,445,00023,281,00024,054,00022,457,00019,571,00019,793,000
Costs and Expenses-0.8%36,958,00037,253,00037,829,00037,296,00035,631,00035,638,00036,094,00036,781,00031,462,00032,654,00033,642,00032,085,00032,406,00028,776,00024,765,00027,954,00030,700,00030,166,00030,129,00029,774,00025,647,500
  S&GA Expenses3.5%22,175,00021,429,00020,838,00021,618,00019,879,00019,792,00019,669,00020,888,00017,734,50018,370,00019,250,00017,973,00019,805,00017,726,00014,290,00017,838,00018,804,00018,245,00018,467,00016,434,00015,468,500
  R&D Expenses4.5%7,301,5006,989,0007,363,0006,679,0006,811,0007,050,0007,022,0006,275,0006,302,0006,404,0005,723,0005,748,0004,931,0004,230,0004,071,0004,614,0004,912,0004,181,0004,282,0004,139,0003,806,500
EBITDA Margin30.2%-0.05-0.07-0.08-0.08-0.08-0.08-0.08-0.08-0.08-0.08-0.08-0.09---------
Interest Expenses122.9%1,843,500827,000148,00016,000-40,00061,000249,000354,000-70,500417,000565,000444,000595,000397,00031,00031,0009,0006,00011,00014,000-114,000
EBT Margin4.2%-0.09-0.10-0.10-0.10-0.11-0.11-0.11-0.11-0.11-0.11-0.11-0.12---------
Net Income4.8%-3,893,000-4,089,000-6,660,000-7,074,000-5,415,000-4,318,000-7,740,000-11,475,000-5,286,000-7,141,000-7,898,000-6,660,000-6,010,000-1,479,000-8,105,000-8,192,000-7,038,000-5,571,000-7,022,000-9,504,000-5,224,000
Net Income Margin10.5%-0.14-0.15-0.16-0.17-0.21-0.22-0.25-0.25-0.21-0.22-0.17-0.19---------
Free Cashflow18.9%-1,674,000-2,064,000-4,123,000-11,727,000-5,260,000-5,059,000-9,737,000-16,088,000-8,684,000-10,093,000-8,524,000-13,915,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets1.1%197195192189195196196198208210211197201194170145155154157160160
  Current Assets0.6%88.0087.0086.0089.0098.00102107112127135142135145140140120135137141146151
    Cash Equivalents19.1%37.0031.0023.008.0015.0021.0018.0021.0039.0053.0059.0046.0056.0068.0086.0042.0042.0031.0031.0030.0030.00
  Inventory0.0%23.0023.0021.0020.0019.0019.0019.0017.0017.0015.0013.0013.0013.0012.0013.0015.0014.0014.0014.0013.0012.00
  Net PPE---------63.0056.0051.0044.0038.0036.0025.0020.0015.0012.0010.009.008.00
Liabilities4.5%10197.0094.0092.0094.0094.0094.0094.0095.0095.0092.0078.0078.0072.0050.0021.0022.0019.0019.0020.0013.00
  Current Liabilities14.2%30.0027.0024.0021.0024.0024.0024.0023.0024.0023.0022.0022.0023.0019.0014.0019.0021.0017.0016.0016.0013.00
  Long Term Debt-100.0%-46.0046.0046.0046.0045.0045.0045.0045.0046.0046.0032.0032.0032.0032.001.00-2.002.003.000.00
    LT Debt, Current--------------2.002.002.002.002.002.001.000.00
    LT Debt, Non Current0.5%47.0046.0046.0046.0046.0045.0045.0045.0045.0046.0046.0032.0032.0019.00-1.00-2.002.003.000.00
Shareholder's Equity-2.2%96.0098.0097.0098.00101101102104113115119120123122120124132135138141147
  Retained Earnings-1.4%-281-277-273-266-259-254-249-242-230-225-218-210-203-197-196-188-179-172-167-160-150
  Additional Paid-In Capital0.5%377375370364360355351346343340336330326319316312312308305301297
Shares Outstanding0.2%43.0043.0043.0043.0042.0042.0042.0042.0042.0041.0041.0041.00---------
Float-------222---642---217---540--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-113.0%-2111,626292-7,4231,362-689-5,688-11,051-1,514-376-695-10,8202,8372,618-7,029-8,052-3,330-1,864-5,811-8,867-4,976
  Share Based Compensation-72.0%1,3274,7475,3902,9544,1543,8494,9102,6781,5092,9113,8052,6942,7452,9472,2225562,9202,3952,6742,3151,625
Cashflow From Investing-104.6%-2775,99414,322-786-1,2092,9712,279-7,241-13,585-6,777-4,157870-19,352-21,13014,9698,55013,5869214,9947,7708,544
Cashflow From Financing8260.0%4185.0089863381321567195.001,04380518,0875174,51519136,096-3289136202,1733251,097
  Buy Backs-------------6.008.0017.00639-----

AXGN Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]   
Revenues$ 159,012$ 138,584$ 127,358
Cost of goods sold31,13824,14722,931
Gross profit127,874114,437104,427
Costs and expenses:   
Sales and marketing86,06080,22873,328
Research and development28,33327,15824,177
General and administrative34,94336,75832,338
Total costs and expenses149,336144,144129,843
Loss from operations(21,462)(29,707)(25,416)
Other (expense) income:   
Investment income1,48756993
Interest expense(2,835)(624)(1,356)
Change in fair value of derivatives1,5311,044(28)
Other expense(437)(230)(278)
Total other (expense) income, net(254)759(1,569)
Net loss$ (21,716)$ (28,948)$ (26,985)
Weighted average common shares outstanding - basic (in shares)42,878,54342,083,12541,214,889
Weighted average common shares outstanding - diluted (in shares)42,878,54342,083,12541,214,889
Loss per common share - basic (in USD per share)$ (0.51)$ (0.69)$ (0.65)
Loss per common share - diluted (in USD per share)$ (0.51)$ (0.69)$ (0.65)

AXGN Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 31,024$ 15,284
Restricted cash6,0026,251
Investments033,505
Accounts receivable, net of allowance for doubtful accounts of $337 and $650, respectively25,14722,186
Inventory23,02018,905
Prepaid expenses and other2,8111,944
Total current assets88,00498,075
Property and equipment, net88,73079,294
Operating lease right-of-use assets15,56214,369
Intangible assets, net4,5313,649
Total assets196,827195,387
Current liabilities:  
Accounts payable and accrued expenses28,88322,443
Current maturities of long-term lease obligations1,5471,310
Total current liabilities30,43023,753
Long-term debt, net of debt discount and financing fees46,60345,712
Long-term lease obligations21,14220,405
Debt derivative liabilities2,9874,518
Total liabilities101,16294,388
Commitments and contingencies - see Note 14
Shareholders’ equity:  
Common stock, $0.01 par value per share; 100,000,000 shares authorized; 43,124,496 and 42,445,517 shares issued and outstanding431424
Additional paid-in capital376,530360,155
Accumulated deficit(281,296)(259,580)
Total shareholders’ equity95,665100,999
Total liabilities and shareholders’ equity$ 196,827$ 195,387
AXGN
AxoGen, Inc., together with its subsidiaries, develops and markets technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.
 CEO
 WEBSITEwww.axogeninc.com
 EMPLOYEES394

AxoGen Inc Frequently Asked Questions


What is the ticker symbol for AxoGen Inc? What does AXGN stand for in stocks?

AXGN is the stock ticker symbol of AxoGen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AxoGen Inc (AXGN)?

As of Wed Mar 27 2024, market cap of AxoGen Inc is 335.71 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AXGN stock?

You can check AXGN's fair value in chart for subscribers.

What is the fair value of AXGN stock?

You can check AXGN's fair value in chart for subscribers. The fair value of AxoGen Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of AxoGen Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AXGN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is AxoGen Inc a good stock to buy?

The fair value guage provides a quick view whether AXGN is over valued or under valued. Whether AxoGen Inc is cheap or expensive depends on the assumptions which impact AxoGen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AXGN.

What is AxoGen Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, AXGN's PE ratio (Price to Earnings) is -15.46 and Price to Sales (PS) ratio is 2.11. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AXGN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on AxoGen Inc's stock?

In the past 10 years, AxoGen Inc has provided 0.081 (multiply by 100 for percentage) rate of return.